Key facts
- Onena Medicines’s last known valuation is $2.1M (May 2022).
- It has raised $2.5M; the latest was Later Stage VC in Mar 2025.
- Notable investors include Plug and Play Tech Center, MassChallenge, StartX (US), Zürcher Kantonalbank, Avanteca Partners — 12 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Onena Medicines
- ·The full record, as it builds
Funding rounds
No funding rounds for Onena Medicines are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Onena Medicines
Developer of an antibody drug discovery platform designed to reprogram cancer cells to treat advanced cancers, centered around proprietary artificial intelligence. The company's platform designs custom antibodies with high selectivity and specificity linked to proprietary cellular reprogramming lab assays, its drugs modulate activities of a novel set of growth factors called dual smad inhibiting protein dips, thought to drive the growth and spread of cancer, enabling physicians to get access to novel drugs in areas of unmet medical needs.
- Sector
- Healthcare
- HQ
- Allschwil, Switzerland
- Founded
- 2019
- Employees
- 10
- Website
- onenameds.com/
- Ownership
- Privately Held (backing)
Onena Medicines doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Onena Medicines shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Onena Medicines in its N-PORT filings yet. We sweep new filings monthly.